Phenotypes Associated with This Genotype

Genotype
MGI:5818157

cn4

• Allelic Composition: Tg(Tal1-cre/ERT)1Jrg/0; Tsc1^tm1Djk/Tsc1^tm1Djk
• Genetic Background: involves: 129S4/SvJae * C57BL/6

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

vision/eye

abnormal retina morphology ( J:231316 )

• mice administered tamoxifen from P1 to P2 show an approximate 2-fold increase in the number of mitotic cells per field in the retina

abnormal retina vasculature morphology ( J:231316 )

• mice administered tamoxifen from P1 to P3 exhibit increased vascular branching and endothelial cell coverage in P5 retinas

neoplasm

increased liver tumor incidence ( J:231316 )

• at 3-4 months after tamoxifen administration, nearly 50% of mice develop liver tumors and by 6-8 months after tamoxifen, almost all mice develop liver tumors

increased metastatic potential ( J:231316 )

• small metastatic nodules are seen in the lymphatic vessels near primary tumors of tamoxifen treated mice

• macrometastases are commonly present in lymph nodes and seen in distant sites such as the sternal musculature at lower frequencies

increased hemangiosarcoma incidence ( J:231316 )

• mice administered tamoxifen at 2 months of age develop endothelial proliferative lesions from vascular malformations that lead to vascular tumors (angiosarcoma/lymphangiosarcoma); cutaneous tumors in tails and paws and liver tumors develop at 3 months or more after tamoxifen treatment

• cutaneous tumors are also seen on the lips and legs at later time points

• at 3-4 months and 6-8 months after tamoxifen administration, about 30% and 80% of mice develop cutaneous tumors, respectively

• poorly differentiated cutaneous lymphangiosarcomas are highly invasive

• mice treated with rapamycin starting 1 week after tamoxifen administration, do not develop cutaneous or liver tumors

• mice treated with rapamycin after the formation of tumors at 3 months after tamoxifen administration show halted tumor progression and even reduced tumor size and improved survival

• mice treated with axitinib after the formation of tumors at 5 months after tamoxifen show decreased proliferation of tumors, however tumors do not shrink and the number of apoptotic cells remains similar to untreated mice

increased extremity angiosarcoma incidence ( J:231316 )

• cutaneous tumors are seen on paws and legs of tamoxifen treated mice

• poorly differentiated cutaneous lymphangiosarcomas on the extremities show local invasion into bone

cardiovascular system

abnormal retina vasculature morphology ( J:231316 )

• mice administered tamoxifen from P1 to P3 exhibit increased vascular branching and endothelial cell coverage in P5 retinas

increased angiogenesis ( J:231316 )

• mice administered tamoxifen from P1 to P3 exhibit increased vascular branching and endothelial cell coverage in P5 retinas

homeostasis/metabolism

edema ( J:231316 )

• 1 month after tamoxifen administration, some mice develop edema, with swelling in paws and tails

liver/biliary system

increased liver tumor incidence ( J:231316 )

• at 3-4 months after tamoxifen administration, nearly 50% of mice develop liver tumors and by 6-8 months after tamoxifen, almost all mice develop liver tumors